Brief: Meiragtx Receives Clinical Development Milestone Payment From Janssen
27/01/2022 14:25
Jan 27 (Reuters) - MeiraGTx Holdings PLC MGTX.O :
* MEIRAGTX RECEIVES CLINICAL DEVELOPMENT MILESTONE PAYMENT
FROM
JANSSEN
* MEIRAGTX HOLDINGS PLC - RECEIVED $30 MILLION CASH
MILESTONE
PAYMENT FROM JANSSEN PHARMACEUTICALS
* MEIRAGTX HOLDINGS PLC - RECEIVED PAYMENT FOR A CLINICAL
MILESTONE IN PHASE 3 LUMEOS TRIAL OF BOTARETIGENE SPAROPARVOVEC
(AAV-RPGR)
Source text for Eikon: ID:nGNX1hYHXn
Further company coverage: MGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MeiraGTx Holdings
See all newsU.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
MeiraGTx gains; reports over $200 mln in license revenue
MeiraGTx Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
MeiraGTx Q2 revenue jumps on Reogen license revenue
Brief: Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For Treatment Of Friedreich's Ataxia